Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Johnson & Johnson (NYSE:JNJ)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on June 06th, the Representative disclosed that they had bought between $15,001 and $50,000 in Johnson & Johnson stock on May 30th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
• Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
• Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
• Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
• Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
• Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.

Johnson & Johnson Trading Up 0.5%

NYSE:JNJ traded up $0.87 during mid-day trading on Monday, hitting $164.57. The company had a trading volume of 1,492,835 shares, compared to its average volume of 8,115,675. The firm has a market cap of $395.98 billion, a P/E ratio of 17.62, a P/E/G ratio of 2.08 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The business's fifty day moving average is $154.29 and its two-hundred day moving average is $155.12. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the firm earned $2.82 EPS. Johnson & Johnson's revenue for the quarter was up 5.8% compared to the same quarter last year. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.16%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Morgan Stanley boosted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday. Raymond James Financial lowered their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Guggenheim lifted their target price on Johnson & Johnson from $164.00 to $167.00 and gave the stock a "neutral" rating in a research note on Thursday. Royal Bank Of Canada lifted their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday. Finally, Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $172.87.

Hedge Funds Weigh In On Johnson & Johnson

Several hedge funds have recently bought and sold shares of JNJ. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson in the fourth quarter worth about $29,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $32,000. Conquis Financial LLC bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $33,000. Finally, Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 69.55% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.